FDA re­jects Fi­bro­Gen's ane­mia drug, de­mand­ing an ad­di­tion­al clin­i­cal tri­al

Less than a month since an FDA ad­comm vot­ed al­most unan­i­mous­ly against ap­prov­ing As­traZeneca and Fi­bro­Gen’s ane­mia drug rox­adu­s­tat as a treat­ment of ane­mia due …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER